Terms: = Ovarian cancer AND NFATC2, ENSG00000101096, 4773, Q13469, NFATP, NFAT1, KIAA0611
3 results:
1. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
[TBL] [Abstract] [Full Text] [Related]
2. [Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian National Institute of Neoplastic Diseases].
Alcarraz C; Muñiz J; Mas L; Olivera M; Morante Z; Alvarez M; Mantilla R; Araujo J; Pinto J
Rev Peru Med Exp Salud Publica; 2018; 35(1):46-54. PubMed ID: 29924276
[TBL] [Abstract] [Full Text] [Related]
3. Huwe1 Sustains Normal ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-
Yang D; Sun B; Zhang X; Cheng D; Yu X; Yan L; Li L; An S; Jiang H; Lasorella A; Iavarone A; Zhang S; Zou F; Zhao X
Cancer Res; 2017 Sep; 77(18):4773-4784. PubMed ID: 28687618
[TBL] [Abstract] [Full Text] [Related]
